ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS

Informations projet

UNITE4TB

N° de convention de subvention: 101007873

DOI 10.3030/101007873

Date de signature de la CE 29 Juin 2021

Date de début 1 Juin 2021

Date de fin 31 Mai 2028

Financé au titre de

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coût total € 185 000 000,00

Contribution de l’UE € 92 500 000,00

Coordonné par

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Netherlands

Livrables

Documents, reports (6)

Report of kick-off meeting

Report of kickoff meeting

Communication and dissemination plan
Establish CAG
Establish SAB and RAB
Report of first annual consortium meeting
Establish EAB

Other (2)

Inaugural meeting with communication professionals of the partners in the consortium
Establish Young Investigators Group

Websites, patent fillings, videos etc. (1)

Visual identity and communication toolkit, including project website

Visual identity and communication toolkit including project website

Publications

Peer reviewed articles (5)

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Auteurs: Keutzer L, You H, Farnoud A, Nyberg J, Wicha SG, Maher-Edwards G, Vlasakakis G, Moghaddam GK, Svensson EM, Menden MP, Simonsson USH, On Behalf Of The UNITE4TB Consortium
Publié dans: Pharmaceutics, 2022, ISSN 1999-4923
Éditeur: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics14081530

Tuberculosis: current challenges and beyond

Auteurs: Raquel Villar-Hernández, Arash Ghodousi, Olha Konstantynovska, Raquel Duarte, Christoph Lange, Mario Raviglione on behalf of the UNITE4TB Consortium
Publié dans: Breath, 2023, ISSN 2073-4735
Éditeur: European Respiratory Society
DOI: 10.1183/20734735.0166-2022

Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies

Auteurs: Heyckendorf J, Georghiou SB, Frahm N, Heinrich N, Kontsevaya I, Reimann M, Holtzman D, Imperial M, Cirillo DM, Gillespie SH, Ruhwald M, Consortium UNITE4TB
Publié dans: Clinical Microbiology Reviews, Numéro 21 March 2022, 2022, Page(s) n/a, ISSN 1098-6618
Éditeur: American Society for Microbiology
DOI: 10.1128/cmr.00227-21

Implementing molecular tuberculosis diagnostic methods in limited-resource and high-burden countries

Auteurs: Anca Vasiliu, Antonia Morita Iswari Saktiawati, Raquel Duarte, Christoph Lange, Daniela Maria Cirillo on behalf of the UNITE4TB Consortium
Publié dans: Breath, 2023, ISSN 2073-4735
Éditeur: European Respiratory Society
DOI: 10.1183/20734735.0226-2022

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

Auteurs: Mockeliunas L, Faraj A, van Wijk RC, Upton CM, van den Hoogen G, Diacon AH, Simonsson USH
Publié dans: Front. Pharmacol., 2023, ISSN 1663-9812
Éditeur: Frontiers Media S.A.
DOI: 10.3389/fphar.2023.1150243

Non-peer reviewed articles (1)

UNITE4TB: a new consortium for clinical drug and regimen development for TB

Auteurs: Boeree, M. J.; Lange, C.; Thwaites, G; Paton, N ; de Vrueh, R.; Barros, D.; Hoelscher, M.; on behalf of the UNITE4TB Consortium
Publié dans: International Union Against Tuberculosis and Lung Disease, Numéro Volume 25, Number 11, 1 November 2021, 2021, Page(s) 886-889, ISSN 1027-3719
Éditeur: International Union Against Tuberculosis And Lung Disease/Union Internationale Contre la Tuberculose et les Maladies Respiratories
DOI: 10.5588/ijtld.21.0515